MétaCan
Menu
Back to cohort
Record W2884345621 · doi:10.1111/adb.12645

Efficacy and safety of sodium oxybate in alcohol‐dependent patients with a very high drinking risk level

2018· review· en· W2884345621 on OpenAlexaff
Wim van den Brink, Giovanni Addolorato, Henri‐Jean Aubin, Amine Benyamina, Fabio Caputo, Maurice Demattéis, Antoni Gual, Otto‐Michael Lesch, Karl Mann, Icro Maremmani, David Nutt, François Paillé, Pascal Perney, Jürgen Rehm, Michel Reynaud, Nicolas Simon, Bo Söderpalm, Wolfgang H. Sommer, Rainer Spanagel

Bibliographic record

VenueAddiction Biology · 2018
Typereview
Languageen
FieldNeuroscience
TopicNeurotransmitter Receptor Influence on Behavior
Canadian institutionsPublic Health OntarioUniversity of TorontoCentre for Addiction and Mental Health
Fundersnot available
KeywordsMedicineAlcoholPopulationAbstinenceAlcohol dependenceAlcohol use disorderPsychiatryEnvironmental health

Abstract

fetched live from OpenAlex

Abstract Medication development for alcohol relapse prevention or reduction of consumption is highly challenging due to methodological issues of pharmacotherapy trials. Existing approved medications are only modestly effective with many patients failing to benefit from these therapies. Therefore, there is a pressing need for other effective treatments with a different mechanism of action, especially for patients with very high (VH) drinking risk levels (DRL) because this is the most severely affected population of alcohol use disorder patients. Life expectancy of alcohol‐dependent patients with a VH DRL is reduced by 22 years compared with the general population and approximately 90 000 alcohol‐dependent subjects with a VH DRL die prematurely each year in the EU (Rehm et al. ). A promising new medication for this population is sodium oxybate, a compound that acts on GABAB receptors and extrasynaptic GABAA receptors resulting in alcohol‐mimetic effects. In this article, a European expert group of alcohol researchers and clinicians summarizes data (a) from published trials, (b) from two new—as yet unpublished—large clinical trials (GATE 2 (n = 314) and SMO032 (n = 496), (c) from post hoc subgroup analyses of patients with different WHO‐defined DRLs and (d) from multiple meta‐analyses. These data provide convergent evidence that sodium oxybate is effective especially in a subgroup of alcohol‐dependent patients with VH DRLs. Depending on the study, abstinence rates are increased up to 34 percent compared with placebo with risk ratios up to 6.8 in favor of sodium oxybate treatment. These convergent data are supported by the clinical use of sodium oxybate in Austria and Italy for more than 25 years. Sodium oxybate is the sodium salt of γ‐hydroxybutyric acid that is also used as a recreational (street) drug suggestive of abuse potential. However, a pharmacovigilance database of more than 260 000 alcohol‐dependent patients treated with sodium oxybate reported very few adverse side effects and only few cases of abuse. We therefore conclude that sodium oxybate is an effective, well‐tolerated and safe treatment for withdrawal and relapse prevention treatment, especially in alcohol‐dependent patients with VH DRL.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.002
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.058
GPT teacher head0.315
Teacher spread0.256 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations73
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueAddiction BiologySame topicNeurotransmitter Receptor Influence on BehaviorFrench-language works237,207